Neurostimulation devices, epilepsy treatment, and medical technology by NeuroPace
NeuroPace Inc launches webinar on RNS System for personalized epilepsy seizure prevention
NeuroPace Inc is inviting participants to a free webinar on its RNS System, an epilepsy device that identifies unique seizure patterns and responds automatically to prevent seizures before they ...
NeuroPace Inc Breakfast Symposium draws strong interest in epilepsy treatment advances
NeuroPace Inc convened with leading epilepsy specialists at ASSFN2026, hosting a Breakfast Symposium on responsive thalamic neuromodulation for drug-resistant epilepsy. The event featured ...
NeuroPace Inc showcases RNS System for drug-resistant epilepsy at ASSFN event
NeuroPace Inc is present at the ASSFN conference, drawing attention to its RNS System designed for adults with drug-resistant focal epilepsy. The company invites attendees to visit Booth 107 to ...
NeuroPace Inc invites ASSFN attendees to explore RNS System for adults with refractory seizures
NeuroPace Inc is engaging with attendees at ASSFN, encouraging visitors to stop by Booth 107 to connect with its clinical team and learn more about the RNS System for drug resistant focal ...
NeuroPace Inc unveils early Nautilus study data at ASSFN breakfast symposium
NeuroPace Inc announced plans to present new findings on responsive thalamic neuromodulation during a breakfast symposium at the ASSFN meeting. The session, scheduled for Monday, June 1 at 7 AM, ...
NeuroPace Inc engages clinicians on RNS System for refractory seizures at ASSFN
NeuroPace Inc is actively presenting its RNS System for the treatment of drug-resistant focal epilepsy at the ASSFN conference, encouraging attendees to visit Booth 107 and interact with its ...
NeuroPace Inc offers exclusive networking dinner for ASSFN fellows limited to 30 seats
NeuroPace Inc has announced an exclusive networking dinner for ASSFN fellows on Saturday, May 30, at 6:00 PM. The event, focused on strategies for building neuromodulation practices after ...
Published study shows long-term benefits of NeuroPace Inc RNS System in drug-resistant epilepsy
NeuroPace Inc announced that the RNS System Post-Approval Study, now published in the Green Journal, reveals sustained long-term outcomes for patients with drug-resistant focal epilepsy. The ...
NeuroPace Inc revenue rises to 22.1 million as RNS System delivers 20 percent YoY growth
NeuroPace Inc reported revenue of 22.1 million for the first quarter of 2026, driven by approximately 20 percent year over year growth in its RNS System segment. The company also raised its full ...
ASSFN Fellows receive invitation to limited seat networking dinner by NeuroPace Inc
NeuroPace Inc will conduct an exclusive networking dinner for ASSFN Fellows on Saturday, May 30 at 6:00 PM. The event aims to bring together professionals in neuromodulation to discuss ...
NeuroPace Inc offers free webinar on RNS System for epilepsy patients
NeuroPace Inc is inviting individuals to a free webinar on the RNS System, its device for epilepsy treatment. The session includes a live Q and A with an epilepsy specialist, aiming to address ...
RNS System delivers life changing outcomes in 3 year post approval study, NeuroPace Inc reveals
NeuroPace Inc has released the results of its three year post approval study on the RNS System, now published in Neurology. The findings suggest that the RNS System is driving a shift in the ...
NeuroPace Inc warns less than 5 percent seizure reduction when medications fail twice
NeuroPace Inc announces that patients who have failed two or more seizure medications face less than a 5 percent chance of further seizure reduction if they continue with medication alone. The ...
NeuroPace Inc introduces RNS System as alternative for patients unresponsive to epilepsy medications
NeuroPace Inc is drawing attention to the estimated 1 million Americans living with drug-resistant epilepsy, particularly those who have failed to control seizures with two or more medications. ...
NeuroPace Inc reports 77 percent drop in GTCs with NAUTILUS trial data
NeuroPace Inc has unveiled results from the NAUTILUS trial, showing a 77 percent median reduction in generalized tonic-clonic seizures (GTCs) over 18 months for patients with drug-resistant ...
NeuroPace Inc unveils NAUTILUS Study results at AAN Annual Meeting
NeuroPace Inc is set to present new findings from the NAUTILUS Study, the first and only randomized trial of neuromodulation for drug-resistant idiopathic generalized epilepsy (IGE), at the 2026 ...
NeuroPace Inc unveils NAUTILUS Study findings on neuromodulation for drug-resistant IGE
NeuroPace Inc is drawing attention to the latest results from its NAUTILUS Study, the first randomized trial to evaluate neuromodulation therapy for patients with drug-resistant idiopathic ...
NeuroPace Inc urges epilepsy patients to evaluate RNS System through online quiz
NeuroPace Inc is calling on individuals with uncontrolled seizures to participate in a brief online quiz to determine if the RNS System could be a suitable treatment option for them. The company, ...
NeuroPace Inc RNS System reduces seizure frequency in epilepsy patient Brian
NeuroPace Inc reports that Brian, who experienced focal epilepsy following a traumatic brain injury, has seen a reduction in seizures after adopting the RNS System for treatment. This improvement ...
